World Lifestyler
  • Art & Culture
    • Architecture
    • Art & Exhibitions
    • Books
    • Design
    • Film & Music
  • Competitions
    • Dining Experiences
    • Hotel Stays
    • Luxury Experiences
    • Product Giveaways
    • Reader Exclusives
    • Travel Giveaways
  • Food & Drink
    • Chefs
    • Coffee Culture
    • Food Destinations
    • Recipes
    • Restaurants
    • Wine & Spirits
  • Lifestyle
    • Design
    • Fashion
    • Health & Wellbeing
    • Homes & Property
    • Love & Romance
  • People
    • Creatives
    • Entrepreneurs
    • Icons
    • Interviews
    • Profiles
    • Rising Talent
  • Travel
    • Adventure & Experience Travel
    • City Guides
    • Destinations
    • Hotels
    • Secret Spots
    • Travel Trends
  • Art & Culture
    • Architecture
    • Art & Exhibitions
    • Books
    • Design
    • Film & Music
  • Competitions
    • Dining Experiences
    • Hotel Stays
    • Luxury Experiences
    • Product Giveaways
    • Reader Exclusives
    • Travel Giveaways
  • Food & Drink
    • Chefs
    • Coffee Culture
    • Food Destinations
    • Recipes
    • Restaurants
    • Wine & Spirits
  • Lifestyle
    • Design
    • Fashion
    • Health & Wellbeing
    • Homes & Property
    • Love & Romance
  • People
    • Creatives
    • Entrepreneurs
    • Icons
    • Interviews
    • Profiles
    • Rising Talent
  • Travel
    • Adventure & Experience Travel
    • City Guides
    • Destinations
    • Hotels
    • Secret Spots
    • Travel Trends
No Result
View All Result
WORLD LIFESTYLER
No Result
View All Result
Home Press Releases Press Releases - Lifestyle

Curasight Announces Preliminary Readout from its Phase 1 Clinical Trial with uTREAT® in Aggressive Brain Cancer (Glioblastoma)

Cision PR Newswire by Cision PR Newswire
June 8, 2026
in Press Releases - Lifestyle
Reading Time: 4 mins read
0
Share on FacebookShare on Twitter

COPENHAGEN, Denmark, June 8, 2026 /PRNewswire/ — Curasight A/S (“Curasight” or “the Company”) (Spotlight: CURAS) announces encouraging preliminary readout from its Phase 1 clinical trial with uTREAT® in patients with aggressive brain cancer (glioblastoma).

A preliminary readout of the Phase 1 clinical trial with uTREAT® in glioblastoma, an aggressive brain cancer, has now been undertaken. The data support:

  • The feasibility and safety of the mode of administration, super-selective intra-arterial cerebral injection (super-SIACI) with local, transient opening of the blood-brain barrier (BBB) using mannitol
  • High uptake and retention in tumor
  • Biodistribution and dosimetry compatible with the ability to deliver a therapeutically relevant radiation dose to the tumor without reaching dose limits for healthy organs
  • The data support continued development of Curasight’s therapeutic program using uTREAT® in aggressive brain cancer

“The preliminary readout of our Phase 1 clinical trial with uTREAT® in glioblastoma is encouraging and supports the ability of our technology to safely deliver therapeutically relevant radiation doses to the tumor without reaching dose limits for healthy organs. With these data, we are confident in moving forward with the Phase 1 trial and the development program for uTREAT®, with the ambition of developing a potentially game-changing radioligand therapy for patients with glioblastoma,” said Curasight’s CEO Ulrich Krasilnikoff.

About the Phase 1 trial with uTREAT® in brain cancer

The trial aims to investigate Curasight’s uTREAT® as a new targeted radioligand therapy for patients with glioblastoma. Participants in the trial are patients with newly diagnosed, verified or suspected GBM. uTREAT® is administered via a catheter directly into the vessels that feed the tumor (super SIACI). To enhance tumor targeting, the blood-brain barrier is transiently opened with the osmotic compound mannitol. The mode of administration is designed to achieve high binding of uTREAT® in tumors while minimizing radiation exposure to healthy organs.

About Curasight’s uPAR theranostic platform

Curasight’s uPAR theranostic platform combines two key technologies – uTRACE® and uTREAT® – both targeting uPAR. uTRACE® is designed to deliver sensitive imaging for diagnosis, while uTREAT® offers a targeted radiopharmaceutical therapy solution. Together, they form an integrated approach to improving the diagnosis and treatment of cancers that express uPAR. Curasight’s ambition is to develop both uTRACE® and uTREAT® to improve diagnosis and treatment of uPAR-expressing cancers.

About high-grade glioma

Treatment of glioblastoma and other high-grade gliomas (WHO grades 3 or 4) presents a significant unmet medical need, necessitating innovative and effective treatments. A total of approx. 65,000 patients are diagnosed with primary brain tumors, and more than 30,000 patients are diagnosed annually with the most aggressive form, glioblastoma, in the US and EU. Approximately 10% of patients with primary brain tumors are children. The prognosis for individuals with glioblastoma is very poor, as approximately 50% of patients die within 14 months, and after five years from diagnosis, only 5% are still alive. External beam radiation is a cornerstone in the therapy of brain cancers. uTREAT® could potentially complement current radiation strategies and reduce radiation exposure to healthy brain tissue due to more specific tumor tissue targeting.

For more information regarding Curasight, please contact:
Ulrich Krasilnikoff, CEO
E-mail: uk@curasight.com
www.curasight.com

This information was brought to you by Cision https://news.cision.com

https://news.cision.com/curasight/r/curasight-announces-preliminary-readout-from-its-phase-1-clinical-trial-with-utreat–in-aggressive-b,c4358770

The following files are available for download:

https://mb.cision.com/Main/19744/4358770/4137661.pdf

Curasight_PR_Prel_Readout_080626

 

Cision View original content:https://www.prnewswire.co.uk/news-releases/curasight-announces-preliminary-readout-from-its-phase-1-clinical-trial-with-utreat-in-aggressive-brain-cancer-glioblastoma-302793816.html

Cision PR Newswire

Cision PR Newswire

Related Posts

The One Where SHEGLAM Meets FRIENDS

October 26, 2026

Rapidus and HCLTech announce partnership for next-generation semiconductor technologies

October 26, 2026

Parloa’s Agent Management Platform now sold as an SAP Solution Extension for agentic customer interactions

October 26, 2026

Temu Partners with Spain’s Recyclia to Support Seller Extended Producer Responsibility

October 26, 2026

SUNON Brings AI, Nature and Human-Centered Design to ORGATEC 2026

October 26, 2026

Innovent Announces NMPA Acceptance of a New Indication Application of Sintilimab for the Treatment of Advanced Melanoma

October 26, 2026

Popular News

  • What price data reveals about the fastest-changing areas

    What price data reveals about the fastest-changing areas

    0 shares
    Share 0 Tweet 0
  • How to adjust to shorter days after the clocks change: Why winter is a time to slow down, not push through

    0 shares
    Share 0 Tweet 0
  • CASI at COP31 Called for Measures to Enhance Bankability of Sustainable Projects via Capacity-building

    0 shares
    Share 0 Tweet 0
  • What it’s really like to be tackling knife crime

    0 shares
    Share 0 Tweet 0
  • Bank Leumi Delivers Strong Third Quarter 2026 Results with High Growth in Loan Portfolio and an Efficiency Ratio Among the Best Globally; Net Income Reached NIS $3B ($979M), ROE of 16.9% and Dividend Distribution of NIS 1.5 ($490M)

    0 shares
    Share 0 Tweet 0

About & Contact

  • About Us
  • Branding Style Guide
  • Contact Us
  • Help Centre
  • Media Kit
  • Site Map

Explore Content

  • Events
  • Newsletter
  • Press Releases
  • Topics

Legal & Privacy

  • Advertiser & Partner Policy
  • Communications & Newsletter Policy
  • Contributor Agreement
  • Copyright Policy
  • Privacy Policy
  • Prohibited Content Policy
  • Terms of Service

Tiny Media Brands

  • Silicon Valleys Journal
  • The AI Journal
  • The City Banker
  • The Wall Street Banker
  • World Lifestyler

© 2025 World Lifestyler

No Result
View All Result
  • Home

© 2025 World Lifestyler